Skip to main content

Table 2 Univariate analyses, multivariate analyses of preoperative prognostic factors influencing cancer-specific survival outcomes in the training cohort

From: Development and validation of a preoperative nomogram for predicting survival of patients with locally advanced prostate cancer after radical prostatectomy

VariableUnivariate analyses (KM) p-valueUnivariate analyses (CIF) p-valueMultivariate Cox regression analyses HR (95%CI)P-valueMultivariate Competing risk analyses sdHR (95%CI)P-value
Age0.0410.047    
 < 50  Ref. Ref. 
 50–59  1.111 (0.440–2.804)0.8241.110 (0.440–2.802)0.826
 60–69  0.805 (0.321–2.0203)0.6450.803 (0.320–2.015)0.641
 > 69  1.291 (0.495–3.373)0.6021.284 (0.492–3.355)0.609
Race0.8600.852    
 White  Ref. Ref. 
 Black  0.988 (0.587–1.661)0.9620.987 (0.587–1.661)0.962
 Other  0.961 (0.487–1.898)0.9080.960 (0.486–1.897)0.907
Marital Status0.7900.815    
 Married  Ref. Ref. 
 Single  1.004 (0.675–1.495)0.9841.003 (0.674–1.493)0.988
 Unknown  1.193 (0.602–2.364)0.6131.189 (0.600–2.357)0.619
T stage0.3000.304    
 T1–2  Ref. Ref. 
 T3–4  6.511 (0.897–47.269)0.0646.493 (0.895–47.142)0.064
N stage< 0.001< 0.001    
 N0  Ref. Ref. 
 N1  2.431 (1.695–3.489)< 0.0012.429 (1.693–3.483)< 0.001
PSA level (ng/ml)< 0.001< 0.001    
 ≤ 10  Ref. Ref. 
 10–20  1.141 (0.765–1.702)0.5191.140 (0.764–1.701)0.521
 > 20  1.472 (0.962–2.253)0.0751.473 (0.962–2.253)0.075
GS biopsy< 0.001< 0.001    
 ≤ 6  Ref. Ref. 
 7 (3 + 4)  4.252 (1.277–14.152)0.0184.253 (1.2779–14.157)0,018
 7 (4 + 3)  6.096 (1.827–20.338)0.0036.099 (1.828–20.349)0.003
 8  9.796 (2.972–32.286)< 0.0019.8068 (2.975–32.322)< 0.001
 ≥ 9  18.879 (5..88–61.576)< 0.00118.888 (5.791–61.605)< 0.001
% positive core biopsy< 0.001< 0.001    
 00–25%  Ref. Ref. 
 25–50%  1.099 (0.599–2.018)0.7601.100 (0.599–2.020)0.758
 50–75%  1.145 (0.604–2.173)0.6781.145 (0.604–2.173)0.678
 75–100%  2.176 (1.219–3.8837)0.0092.174 (1.218–3.881)0.009
  1. Abbreviation: KM Kaplan-Meier method, CIF Cumulative incidence function, sdHR Subdistribution hazard ratio, Ref. Reference, % positive core biopsy Percent of positive cores at biopsy